Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ · Healthcare
Amylyx Pharmaceuticals, Inc. Common Stock annual/quarterly total liabilities history from 2021 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for the quarter ending December 31, 2025 were 27.4M, a 5.14% decrease year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2025 were 27.4M, a 5.14% decrease from 2024.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2024 were 28.9M, a 65.64% decrease from 2023.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2023 were 84.0M, a 65.25% increase from 2022.
- Amylyx Pharmaceuticals, Inc. Common Stock total liabilities for 2022 were 50.8M.
Total Liabilities
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Amylyx Pharmaceuticals, Inc. Common Stock Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $27 |
| 2024 | $29 |
| 2023 | $84 |
| 2022 | $51 |
| 2021 | $17 |
| Amylyx Pharmaceuticals, Inc. Common Stock Quarterly Total Liabilities (Millions of US $) | |
|---|---|
| 2025-12-31 | $27 |
| 2024-12-31 | $29 |
| 2023-12-31 | $84 |
| 2022-12-31 | $51 |
| 2021-12-31 | $17 |
Amylyx Pharmaceuticals, Inc. Common Stock Total Liabilities — FAQ
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) total liabilities over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AMLX's total liabilities history?
The chart and table above show Amylyx Pharmaceuticals, Inc. Common Stock's total liabilities by year and by quarter, including the growth rate.